IO Biotech, Inc.

As of September 30, 2025, IO Biotech, Inc. has 69.69M shares outstanding.

As of September 30, 2025, IO Biotech, Inc. maintains a current ratio of 2.01, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1,988.91, indicating moderate leverage, while an interest coverage ratio of -80.02 demonstrates limited ability to service its debt obligations.

Over the twelve months ended September 30, 2025, IO Biotech, Inc. posted a negative return on equity (ROE) of -240.48, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -136.03, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 80.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended September 30, 2025, IO Biotech, Inc. recorded an income tax benefit of -955,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -89.30M and -88.35M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 21, 2026, IO Biotech, Inc.'s stock has declined approximately 99.99% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.14.

Over the twelve months ended September 30, 2025, IO Biotech, Inc. generated - - in revenue and converted that into -88.35M in net income, yielding earnings per share of -1.34. EBITDA reached -91.14M, while operating income came in at -92.05M.

As of September 30, 2025, IO Biotech, Inc. holds 30.66M in cash and equivalents against 18.12M in total debt, resulting in a net debt position of -14.00M. Total book value stands at 911,000.00, with working capital of 18.52M providing operational flexibility.

IO Biotech, Inc. produced -81.00M in operating cash flow over the twelve months ended September 30, 2025. After subtracting -69,000.00 in capital expenditures, free cash flow totaled -81.06M - equivalent to -1.23 per share.